Related Experiment Videos
Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis
1Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Alimentary Pharmacology & Therapeutics
|June 1, 1995
Summary
Rectal 5-aminosalicylate (ASA) is effective for active distal ulcerative colitis, significantly improving remission and endoscopic outcomes. Further research is needed for 4-ASA and optimal maintenance regimens.
Area of Science:
- Gastroenterology
- Clinical Pharmacology
Background:
- Distal ulcerative colitis management requires effective therapies for exacerbations and remission maintenance.
- Rectal aminosalicylates (ASA) are a key treatment modality for ulcerative colitis.
Purpose of the Study:
- To meta-analyze evidence on rectal 5-ASA and 4-ASA for distal ulcerative colitis exacerbation and remission.
- To quantify the efficacy of these therapies.
Main Methods:
- Systematic review and meta-analysis of randomized, double-blind controlled trials.
- Included 19 trials from MEDLINE and bibliographies, with dual observer data extraction.
- Focused on trials of rectal 5-aminosalicylate (ASA) and 4-ASA.
Main Results:
- Rectal 5-ASA significantly improved remission (OR 7.36), endoscopic (OR 10.04), and histological outcomes (OR 10.31) compared to placebo.
- Rectal 5-ASA demonstrated strong efficacy in maintaining remission (OR 16.22).
- 4-ASA showed benefits comparable to prednisolone in active disease; no dose-response was observed for ASA.
Conclusions:
- Rectal 5-aminosalicylate (5-ASA) is an effective treatment for active distal ulcerative colitis.
- Further investigation is warranted for 4-ASA efficacy, dose-response relationships, and optimal remission maintenance strategies.